Regulatory T cells, B cells, and other immune cell populations

Regulatory T cells (Tregs), B cells, and other immune cell populations represent the cellular components of the adaptive and innate immune systems rather than a single molecular target. Tregs are a specialized lineage of CD4+ T cells defined by the expression of the transcription factor FOXP3, which are critical for maintaining self-tolerance and preventing autoimmune pathology (Source: Nature Reviews Immunology, NIH). B cells are responsible for antibody production and antigen presentation, playing a central role in the humoral immune response (Source: StatPearls). Other populations, such as natural killer (NK) cells and myeloid cells, contribute to pathogen clearance and tumor surveillance. In therapeutic contexts, these cells are targeted by drugs like Rituximab (targeting CD20 on B cells) or checkpoint inhibitors like Pembrolizumab (targeting PD-1 on T cells) to modulate immune activity in cancer and autoimmune diseases (Source: PubMed, FDA). Because this entry encompasses multiple distinct cell types with diverse biological roles, it is classified as a broad cellular category rather than a discrete therapeutic molecule. Targeting these populations requires precision to avoid broad immunosuppression while achieving the desired clinical outcome in oncology or rheumatology.

Other names

TregsB lymphocytesLeukocytesImmune cell subsetsLymphocytes

Therapeutic strategies involve the depletion of specific cell subsets via antibody-dependent cellular cytotoxicity, the blockade of costimulatory or inhibitory checkpoints to modulate activation, and the use of immunosuppressants to inhibit intracellular signaling and proliferation.